# Denali Therapeutics Inc. (DNLI) — divestiture/asset_sale [completed]
Source: SEC API (secapi.ai) · situation sit_3d6a77c7e52b110ca82a · retrieved 2026-08-11T16:09:39.593Z

## Overview
Denali Therapeutics Inc. is a biopharmaceutical company that develops therapeutic treatments; it received a Rare Pediatric Disease Priority Review Voucher following FDA approval of AVLAYAHTM (tividenofusp alfa) for Hunter syndrome.

On July 27, 2026, Denali Therapeutics Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to a large pharmaceutical company pursuant to an asset purchase agreement dated June 12, 2026. The company received the PRV following FDA approval of AVLAYAHTM (tividenofusp alfa) for Hunter syndrome (mucopolysaccharidosis type II; MPS II) in March 2026. Denali received gross proceeds of $195.0 million upon closing of the sale.

## Terms
- Counterparty: a large pharmaceutical company · Deal value: $195.0M · Consideration: cash

## Key dates
- Completed 2026-07-27

## Timeline
- 2026-07-28 · 8-K (0001714899-26-000086): 8-K - Denali Therapeutics Inc. — *Denali Therapeutics Inc. is a biopharmaceutical company that develops therapeutic treatments; it received a Rare Pediatric Disease Priority Review Voucher following FDA approval of AVLAYAHTM (tividenofusp alfa) for Hunter syndrome.* On July 27, 2026, Denali Therapeutics Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) to a large pharmaceutical company pursuant to an asset purchase agreement dated June 12, 2026. The company received the PRV following FDA approval of AVLAYAHTM (tividenofusp alfa) for Hunter syndrome (mucopolysaccharidosis type II; MPS II) in March 2026. Denali received gross proceeds of $195.0 million upon closing of the sale.
  https://www.sec.gov/Archives/edgar/data/1714899/0001714899-26-000086.txt

## Citations
- 0001714899-26-000086 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000171489926000086